The First Affiliated Hospital of USTC
Hefei, Anhui, 230000, China
NCT Number: NCT06837077
In order to improve the medication convenience and compliance of patients and facilitates in the long-term control of disease condition, it is planned to reduced the number of injections to one per administration. The study aims to compare the safety and pharmacokinetics data to assess feasibility of single-site and multiple-site injection for administration.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Hefei, Anhui, 230000, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
SHR-1209 single-site subcutaneous injection.
SHR-1209 multiple-site subcutaneous injections.
Time frame: After injection in day 1 and day 57.
Time frame: After injections in day 1 and day 57.
Time frame: After injection in day 1 up to day 56.
Time frame: After injection in day 1 up to day 56.
Time frame: After injection in day 1 up to day 56.
Time frame: Day 68.
Time frame: From Day 1 to Day 169.
Time frame: From Day 1 to Day 169.
Jiangsu HengRui Medicine Co., Ltd.
Industry
A Single-center, Randomized, Crossover, Open-label Phase I Study to Compare the Safety and Pharmacokinetics of SHR-1209 Given as Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07238257
Body Weight, Cardiovascular Diseases
Taoyuan, Taiwan
View Trial DetailsNCT05370950
Dyslipidemias, Hypercholesterolemia
Hefei, Anhui, China
View Trial DetailsNCT06894004
Dyslipidemias, Hypercholesterolemia
St Louis, Missouri, United States
View Trial DetailsNCT06810466
Dyslipidemias, Hypercholesterolemia
Bologna, Italy
View Trial Details